FI/VC  Dolby Family Ventures

http://www.dolbyventures.com





     Office Locations:

999 Brannan Street, Penthouse
San Francisco, CA 94103
Phone: 415-449-1005

 

Stages:

  • Early
  • Seed


 

Industries:

  • Information Technology
  • Life Sciences & Healthcare
  • Media & Digital Media
  • Software & Internet

  •  

    Description:

    Dolby Family Ventures is an early stage venture firm focused on building great technology companies. Dolby Family Ventures is jointly managed by David Dolby, son of Ray Dolby, and veteran venture capitalist Pascal Levensohn. Based in San Francisco, Dolby Family Ventures funds international seed and Series A investments in four sectors: Digital Media, Cloud Services, Security, and HealthCare Technology and Services. Dolby Family Ventures anticipates making four to seven investments per year, with capital at risk of approximately $3 million per company. The fund is not affiliated with Dolby Laboratories, Inc. The Dolby portfolio of family investments includes a wide range of asset classes: private equity, venture capital and real estate.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Alona Cochran Office Manager & Executive Assistant
    Andrew Krowne Managing Director
    Dave Dolby CEO
    Pascal Levensohn Senior Managing Director
    Sourav Kole PhD Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      10/23/2024


      California Catalysts


      CA


      $3,000,000


      Series A-2


      08/06/2024


      NeuroTherapia


      OH


      $12,300,000


      Series B


      05/22/2024


      Progentos Therapeutics


      MA


      $65,000,000


      Series A


      01/24/2024


      Motif Neurotech


      TX


      $18,750,000


      Series A


     

    Portfolio companies include:


      3Scan
        web link


      AltSpaceVR
        web link


      Atmosic Technologies
        web link


      Atomwise


      BASIS Science
        web link


      Bionaut Labs
        web link


      Cala Health


      California Catalysts
        web link


      Cerevance
        web link


      Cortexyme
        web link


      Diamond Age


      Digilens
        web link


      Eargo
        web link


      echo
        web link


      Ecovative Design
        web link


      Eyefluence
        web link


      Genemod
        web link


      Libra Therapeutics
        web link


      Lightform
        web link


      MedaRed


      MedCrypt
        web link


      Mojo Vision
        web link


      Motif Neurotech
        web link


      NeuroTherapia
        web link


      New Matter
        web link


      Paradromics
        web link


      PharmatrophiX
        web link


      Progentos Therapeutics
        web link


      QurAlis


      System1 Biosciences
        web link


      Tetra Discovery Partners
        web link


      TripleBlind
        web link


      Yumanity Therapeutics
        web link


     

    Recent News: